GlaxoSmithKline plc stands to significantly expand the market opportunity for its blockbuster shingles vaccine Shingrix (zoster vaccine recombinant, adjuvanted) with a new approval by the US Food and Drug Administration for prevention of shingles (herpes zoster) use in immunocompromised adults.
The company said that the indication could reach 3 million more people based on the populations it studied, but the...






